Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Reddy's Laboratories Ltd.

www.drreddys.com

Latest From Dr. Reddy's Laboratories Ltd.

Granules Moves Out Of China JV

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

Strategy China

Reality Check? Granules Moves Out Of China JV

Indian firm Granules is exiting its long-standing joint venture for ibuprofen API in China against the backdrop of evolving pollution control norms and the need for growing expenditure there, while emerging supply options have reduced the need for a local JV.

Commercial Strategy

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Biosimilars Commercial

Manufacturing Round-Up: Dr Reddy’s Receives Another Form 483

Dr Reddy’s, Ipca Labs and Yino have received Form 483s over quality control issues. Meanwhile, Bora Pharma, Unichem and Laurus Labs have successful FDA inspections and Indoco Remedies gets its GMP status fully reinstated.

Manufacturing Compliance
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register